The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
AI-powered cardiometabolic wellness platform for India’s workforce
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Subscribe To Our Newsletter & Stay Updated
